Home / Pharma News / Coherus signs licensing deal for bevacizumab biosimilar in the US

Coherus signs licensing deal for bevacizumab biosimilar in the US Posted 07/02/2020

US-based Coherus BioSciences (Coherus) announced on 13 January 2020 that it had entered into a licensing agreement with Chinese biopharmaceutical firm Innovent Biologics (Innovent) for its bevacizumab product, IBI305.

Under the terms of the agreement, Coherus will gain the rights to commercialize Innovent’s biosimilar candidate to Avastin (bevacizumab) in Canada and the US. Coherus will pay up to US$45 million in milestones, including an upfront payment, for its Avastin biosimilar upon achieving certain regulatory and commercialization goals, as well as customary double-digit royalty payments.

In June 2019, Innovent announced positive phase III results for IBI305 from a large safety and efficacy study carried out in China [1]. The application for approval of IBI305 was filed for approval and was accepted by China’s regulatory agency, the National Medical Products Administration (NMPA), in January 2019 and subsequently granted priority review status.

In addition to the bevacizumab product, Coherus has also acquired the option to commercialize Innovent’s rituximab product, IBI301, in Canada and the US. IBI301 was filed for approval and accepted by China’s NMPA in June 2019 [2] and was also subsequently granted priority review status. Financial terms for Innovent’s candidate biosimilar to Rituxan (rituximab) will be the same as for the bevacizumab product if the option is taken.

Coherus plans to file a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) in late 2020 or early 2021 depending on the FDA interaction timing, and to launch directly upon approval. The company anticipates completing a single-dose pharmacokinetic clinical study and certain analytical/bioanalytical exercises to support the US filing.

Coherus already has a biosimilar approved in the US. Udenyca (pegfilgrastim-cbqv) was approved by FDA in November 2018 [3]. The company has also acquired rights to commercialize Bioeq’s Lucentis (ranibizumab) biosimilar, FYB201, in the US.

Denny Lanfear, Chairman and Chief Executive of Coherus says that Innovent’s oncology therapeutics ‘complement Udenyca and advance our core mission to expand choice, improve patient access and lower healthcare costs in the United States’.

Related article
Biosimilars of bevacizumab

References
1. GaBI Online - Generics and Biosimilars Initiative. Positive phase III results for bevacizumab copy biological IBI305 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Feb 7]. Available from: www.gabionline.net/Biosimilars/Research/Positive-phase-III-results-for-bevacizumab-copy-biological-IBI305
2. GaBI Online - Generics and Biosimilars Initiative. Rituximab copy biological accepted for review in China [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Feb 7]. Available from: www.gabionline.net/Biosimilars/News/Rituximab-copy-biological-accepted-for-review-in-China
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Feb 7]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-the-US

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

Source: Coherus, Innovent

Comments (0)

Generics News Research General

more

Biosimilars News Research General

more